Singhs overall message was that current evidence does not support withholding GLP-1 therapy solely because of ocular safety concerns
Who May Qualify Prescribed Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or another GLP-1 receptor agonist Diagnosed with gastroparesis, ileus, bowel obstruction, pancreatitis, gallbladder disease, kidney injury, or NAION Medical records documenting both the prescription and the subsequent diagnosis Meaningful damages hospitalization, surgery, lost income, or permanent impairment Off-label use for weight loss does not disqualify a claim
For example, around the mouth and to support and smooth out lines and wrinkles
Medica Depots support representatives can assist qualified laboratories with guidance on sourcing documentation and supplier verification for research-grade peptide materials
Symptoms extend far beyond painful periods
It's a process of persuasion, not brute force